Pulmatrix, Inc. (PULM)
| Market Cap | 47.52M |
| Revenue (ttm) | 11.26M |
| Net Income (ttm) | -18.73M |
| Shares Out | 46.03M |
| EPS (ttm) | -0.53 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 30 |
| Last Price | $0.845 |
| Previous Close | $0.854 |
| Change ($) | -0.009 |
| Change (%) | -1.09% |
| Day's Open | 0.843 |
| Day's Range | 0.830 - 0.854 |
| Day's Volume | 241,345 |
| 52-Week Range | 0.820 - 3.040 |
Pulmatrix, Inc. (PULM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LEXINGTON, Mass., July 27, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-...
LEXINGTON, Mass., May 11, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pul...
LEXINGTON, Mass., April 15, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-p...
Corrected: Pulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor Portfolio
LEXINGTON, Mass., April 12, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), is re-issuing this press release solely to correct inadvertent typographical errors under the heading "Updated PUR1800 Pr...
LEXINGTON, Mass., April 12, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-p...
LEXINGTON, Mass., March 23, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-p...
LEXINGTON, Mass., March 4, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pu...
LEXINGTON, Mass., Feb. 11, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pu...
LEXINGTON, Mass., Sept. 30, 2020 /PRNewswire/ – Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary and non-pulmonary...
LEXINGTON, Mass., Aug. 7, 2020 /PRNewswire/ -- Pulmatrix, Inc.
Pulmatrix (PULM) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
LEXINGTON, Mass., June 26, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to serious pulmonary and non-pulmonary ...
January has turned out great for biotech stocks thanks to the coronavirus outbreak as well as a general upbeat trend.
Shares of Pulmatrix Inc. more than doubled Monday, rocketing 124% on heavy volume, after the company said it entered into a "binding term sheet" with Cipla Ltd.
About PULM
Pulmatrix, Inc., a clinical stage biopharmaceutical company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug that is in Phase 2b clinical trial... [Read more...]
| Industry Biotechnology | Founded 2003 |
| CEO Teofilo Raad | Employees 20 |
| Stock Exchange NASDAQ | Ticker Symbol PULM |
Financial Performance
In 2020, Pulmatrix's revenue was $12.63 million, an increase of 59.72% compared to the previous year's $7.91 million. Losses were -$19.31 million, -6.25% less than in 2019.
Analyst Forecasts
According to one analyst, the rating for Pulmatrix stock is "Buy" and the 12-month stock price forecast is 5.00.